News

  1. Home
  2. News

Mabgeek Biotech' second antibody drug has received the clinical trial approval notice.

2022-05-23

The second antibody drug "MG-ZG122 humanized monoclonal antibody injection" submitted by Mabgeek Biotech was granted the "Drug Clinical Trial Approval Notice" by the National Medical Products Administration on July 25, 2022. This product is a Class I new drug, and its indications are asthma and chronic obstructive pulmonary disease (COPD).

WeChat Picture_20220726152230


All Rights Reserved by HUNAN MABGEEK BIOTECH CO., LTD  © 2018-2024 mabge.com

湘ICP备2024096314号 公安部备案：31011502015815

We use strictly necessary cookies to maintain an anonymous session and enable the website to function properly.
With your consent, we also use an analytics cookie to help keep article view counts accurate.
It prevents the same browser from repeatedly increasing an article's view count within a short period of time.
This analytics cookie is optional and will only be used if you consent.
You can change or withdraw your choice at any time through your Cookie Settings.
Agree Decline Cookie Settings

Cookie Settings

Necessary Cookies Used to maintain anonymous sessions and guarantee normal website operation, cannot be disabled. [Privacy Policy]  [Cookie Statement]
Close